US Stock MarketDetailed Quotes
CRBP Corbus Pharmaceuticals
- 16.0500
- -0.7000-4.18%
Close Dec 4 16:00 ET
- 16.4300
- +0.3800+2.37%
Post 20:01 ET
195.48MMarket Cap-3407P/E (TTM)
16.8200High15.9101Low433.44KVolume16.8100Open16.7500Pre Close7.04MTurnover5.59%Turnover RatioLossP/E (Static)12.18MShares61.900052wk High1.30P/B124.51MFloat Cap4.937252wk Low--Dividend TTM7.76MShs Float323.4000Historical High--Div YieldTTM5.43%Amplitude2.1100Historical Low16.2320Avg Price1Lot Size
Corbus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -94.29%-13.94M | -14.63%-8.94M | 47.29%-7.97M | 3.85%-36.1M | 19.40%-6.01M | 0.95%-7.18M | 36.21%-7.8M | -42.39%-15.11M | 22.08%-37.54M | 23.16%-7.45M |
| Net income from continuing operations | -37.10%-13.78M | -13.81%-10M | 61.12%-6.9M | -5.33%-44.6M | 26.27%-8.02M | -14.48%-10.05M | 33.70%-8.78M | -88.03%-17.74M | 7.22%-42.35M | -6.03%-10.88M |
| Operating gains losses | ---- | ---- | 572.86%6.41K | -102.72%-20.44K | ---- | ---- | ---- | -100.38%-1.36K | 439.35%751.14K | 51.82%-277.27K |
| Depreciation and amortization | -0.65%152K | -4.94%150.31K | -16.60%151.69K | -16.04%640.6K | -19.95%147.6K | -19.81%153K | -17.68%158.13K | -7.08%181.87K | -53.45%763K | -62.04%184.4K |
| Other non cash items | -51.14%107K | -59.74%91.33K | -6.69%187.67K | 11.03%824.38K | -12.45%177.38K | 20.06%219K | 25.65%226.88K | 13.69%201.12K | -21.89%742.48K | -57.67%202.61K |
| Change In working capital | -210.76%-2.03M | 426.51%488.89K | -204.44%-1.49M | 224.12%4.09M | -54.05%989.31K | 17,075.71%1.83M | 89.93%-149.73K | 136.00%1.42M | 78.98%-3.3M | 192.70%2.15M |
| -Change in prepaid assets | 22.71%-524K | 407.74%424.01K | 318.99%1.23M | -193.46%-1.47M | -169.45%-93.45K | -183.08%-678K | -132.84%-137.78K | -376.26%-561.22K | 16.73%1.57M | 153.15%134.55K |
| -Change in payables and accrued expense | -131.82%-1.37M | 44.04%194.46K | -629.13%-2.76M | 239.27%6.06M | -7.47%1.99M | 723.08%4.32M | 107.62%135.01K | 90.60%-379.01K | 75.65%-4.35M | 150.08%2.15M |
| -Change in other current assets | 7.31%235K | 32.59%228.47K | 157.59%434.54K | 24.03%763.87K | 21.69%203.87K | 41.19%219K | 15.33%172.31K | 17.28%168.69K | 228.21%615.9K | 461.17%167.53K |
| -Change in other current liabilities | 82.00%-365K | -12.15%-358.04K | -117.63%-386.96K | -10.70%-1.26M | -275.37%-1.11M | -601.73%-2.03M | -12.69%-319.26K | 913.58%2.2M | -15.80%-1.14M | -23.67%-294.82K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -94.29%-13.94M | -14.63%-8.94M | 47.29%-7.97M | 3.85%-36.1M | 19.40%-6.01M | 0.95%-7.18M | 36.21%-7.8M | -42.39%-15.11M | 22.08%-37.54M | 23.16%-7.45M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -241.00%-15.37M | -286.66%-16.44M | -1,870.11%-98.24M | 18.51%35.64M | -11.81%10.39M | 282.49%10.9M | 147.11%8.81M | -87.08%5.55M | 140.96%30.07M | 470.74%11.78M |
| Net PPE purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 82.33%-5.35K | --0 |
| Net investment purchase and sale | -241.00%-15.37M | -286.66%-16.44M | -1,870.11%-98.24M | 18.49%35.64M | -11.81%10.39M | 282.49%10.9M | 147.09%8.81M | -87.09%5.55M | 140.99%30.08M | 475.22%11.78M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -241.00%-15.37M | -286.66%-16.44M | -1,870.11%-98.24M | 18.51%35.64M | -11.81%10.39M | 282.49%10.9M | 147.11%8.81M | -87.08%5.55M | 140.96%30.07M | 470.74%11.78M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,150.43%25.04M | 194,039.19%34.96M | 94,412.48%106.58M | -428.57%-2.82M | -912.78%-1.9M | -641.62%-821K | 105.46%18.01K | 65.45%-113.01K | -100.88%-533.62K | -69.49%234.32K |
| Net issuance payments of debt | -1,370.58%-10.9M | -1,391.56%-2.27M | -1,443.86%-2.32M | -438.58%-2.87M | -881.37%-1.83M | -569.35%-741K | 53.97%-151.93K | 54.13%-150.07K | -1,023.53%-533.62K | -69.49%234.32K |
| Net common stock issuance | 45,026.25%35.94M | 17,870.63%30.54M | 311,833.25%115.59M | --244.3K | --117.3K | ---80K | --169.94K | --37.06K | --0 | --0 |
| Net other financing activities | ---- | ---- | ---6.69M | ---190.9K | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,150.43%25.04M | 194,039.19%34.96M | 94,412.48%106.58M | -428.57%-2.82M | -912.78%-1.9M | -641.62%-821K | 105.46%18.01K | 65.45%-113.01K | -100.88%-533.62K | -69.49%234.32K |
| Net cash flow | ||||||||||
| Beginning cash position | 170.05%24.36M | 84.79%14.77M | -18.55%14.39M | -31.17%17.67M | -9.11%11.92M | -65.89%9.02M | -86.14%7.99M | -31.17%17.67M | -70.30%25.68M | -65.30%13.11M |
| Current changes in cash | -247.00%-4.26M | 835.54%9.58M | 103.92%379.44K | 59.03%-3.28M | -45.71%2.47M | 121.76%2.9M | 103.28%1.02M | -130.23%-9.68M | 86.83%-8M | 137.64%4.56M |
| End cash Position | 68.58%20.09M | 170.05%24.36M | 84.79%14.77M | -18.55%14.39M | -18.55%14.39M | -9.11%11.92M | -65.89%9.02M | -86.14%7.99M | -31.17%17.67M | -31.17%17.67M |
| Free cash flow | -94.29%-13.94M | -14.63%-8.94M | 47.29%-7.97M | 3.88%-36.1M | 19.40%-6.01M | 0.95%-7.18M | 36.21%-7.8M | -42.21%-15.11M | 22.14%-37.56M | 23.59%-7.45M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data